Furthermore, in a prospective study, dynamic changes of KRAS mutant ctDNA were observed in association with treatment course in NSCLC patients, whereas the poor prognosis of patients with high levels of ctDNA was also shown [17]. Here, KRAS is linked to non-small cell lung carcinoma.